Kornimate/medical-research-clean huggingface dataset:
accurate test of limb isometric strength (atlis) in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: a strength measurement device called accurate test of limb isometric strength (atlis) was developed to precisely and conveniently measure static limb strength in patients with als. the investigator will compare atlis data with data from the commonly used als outcomes measure, the als functional rating scale-revised (alsfrs-r), as well as an exploratory measure, electrical impedance myography (eim), in a prospective, longitudinal study. both outcomes measures will be performed on 100 subjects collected preferably at bi-monthly clinic visits during the study period.

cedars-sinai medical center will enroll and collect data on 100 subjects. subjects will ideally be tested every 1 to 4 months according to each patient's site visit schedule. subjects will be tested at each visit using atlis, the alsfrs-r questionnaire and eim.

Eligibility criteria:
inclusion criteria: * subjects 18 years or older diagnosed with clinically possible, laboratory supported probable, probable or clinically definite als according to the world federation of neurology revised el escorial criteria. * capable of providing informed consent and complying with trial procedures. * active movement of at least two limbs at the time of study entry * intend to routinely attend clinic for neurological care at the clinical site exclusion criteria: * patients, judged by the site clinical investigator to have medical conditions that may limit their ability to safely exert maximal force using the muscles in their arms and legs will be excluded from this study (e.g. unstable hypertension, significant cardiac disease, significant musculoskeletal disorders, or other medical conditions). * patients judged by the site clinical investigator to have significant clinical evidence of unstable medical or psychiatric illness will be excluded.

Keywords: outcomes measures strength measurement disease progression
an analysis of kinesio® tape on myofascial pain syndrome of the iliotibial band

Conditions: Myofascial Trigger Point Pain

Summary: participants will report for two research sessions. prior to arrival, membership to a club sports team will be confirmed via email. the first session will require one hour, while the second will require 30 minutes. maximum amount of time expected is one and a half hours, over two sessions in 48 hours. the 1st and 2nd sessions will be separated by 48 hours. upon arrival for session 1, informed consent will be obtained along with the following demographic information: age, sex, height, weight, dominant leg, and sport. next, the participant will complete the musculoskeletal questionnaire (mq) in regard to the last 12 months. participants will then be assessed for trigger points in their dominant side iliotibial band via palpation. diagnostic criteria for trigger point will be modeled after travell and simons: taut band, pain upon palpation, referred pain, and a local twitch response. up to four trigger points will be marked on the subject's skin with marker or pen. pain pressure threshold will be obtained via algometer, using the terminology "tell me the first moment you experience pain by verbalizing 'pain' ". then, three pain pressure threshold readings will be taken per trigger point and then averaged by the researcher. kinesiology tape will then be applied to the identified trigger points using the fascial technique. pain pressure threshold will be obtained again with the same protocols 10 minutes after the tape is applied. the participant will be asked to wear the tape for 48 hours. upon arrival for session 2, the application of the tape will be confirmed. with the participant's choice to continue in the study, a third and fourth measurement of pain pressure threshold will be obtained: one with the tape remaining on, and another 10 minutes after removal of the tape. again, three pain pressure threshold readings will be taken per trigger point and then averaged by the researcher.


Eligibility criteria:
inclusion criteria: * member of club sports team exclusion criteria: * acute quadriceps strain in last six months * knee surgery in last six months * acute hamstring strain in last six months * allergy to adhesive * malignancies * cellulitis * skin infection * diabetes * fragile skin
welfare benefits in functional somatic disorders

Conditions: Fibromyalgia; Irritable Bowel Syndrome; Chronic Fatigue Syndrome; Bodily Distress Syndrome; Somatoform Disorders; Medically Unexplained Syndrome; Medically Unexplained Symptoms

Summary: the objective of this observational study is to estimate the number of weeks of welfare benefits, i.e. sickness benefit, unemployment benefit and social assistance, for individuals with functional somatic disorders and compare them to 1. healthy individuals, and 2. individuals with severe physical disease.

functional somatic disorders (fsd) are common conditions characterized by persistent patterns of physical symptoms that cannot be better explained by other physical or mental conditions (1). the conditions may cause severe impairment for the patients who present with reduced physical and mental health, lower social status, and poor labour market association (2-4). in 2005, it was estimated that fsd accounted for 3% of hospitalizations and 10-20% of health care expenses in denmark (5), and a newer danish primary care study has shown patients with fsd to have higher annual health care costs compared with conventionally-defined conditions (6). in other countries, studies in clinical samples have shown increased direct and indirect health care costs of fsd (7, 8) showing a dose-response relationship with severity of the fsd (9). these studies into highly selected clinical samples may induce high risk of selection bias, and studies including random selected general population samples are therefore needed. one canadian population-based study on health care costs of children, adolescents, and young adults with fsd also found increased health care use and costs for this group (10). studies investigating the socioeconomic burden in terms of welfare benefits of fsd in an adult random sample from the general population are, however, lacking. objective to estimate the number of weeks of welfare benefits, i.e. sickness benefit, unemployment benefit and social assistance, for individuals with fsd and compare them to individuals without fsd and individuals with severe physical disease.

Eligibility criteria:
inclusion criteria: * none exclusion criteria: * not born in denmark * not being a danish citizen * pregnancy
construction of a cohort for pan-vascular disease among employees of taizhou people's hospital

Conditions: Cardiovascular Death; Myocardial Infarction; Stroke

Summary: 1. participant recruitment during the annual health check-ups for hospital staff, potential participants are recruited. those who express interest are provided with a detailed explanation of the study's objectives, content, and procedures, and are required to sign an informed consent form. 2. screening phase medical history is collected, including any previous occurrences of myocardial infarction, ischemic or hemorrhagic stroke, or history of coronary, carotid, or peripheral arterial revascularization. 3. baseline data collection 1. health questionnaire survey: collect demographic information, medical history, and data on nutrition, physical activity, and smoking habits through a questionnaire. 2. clinical assessments: conduct the following assessments for all enrolled participants: * high-sensitivity cardiac troponin i and nt-probnp testing * non-invasive arterial stiffness testing * measurement of visceral and subcutaneous fat content * fundus photography * body composition analysis 4 regular follow-up annual follow-up for a total of 10 years. the follow-up includes: 1. . collection of updated demographic information and medical history, as well as repeated questionnaires on nutrition, physical activity, and smoking habits. 2. . reassessment of the following items: * high-sensitivity cardiac troponin i and nt-probnp testing * non-invasive arterial stiffness testing * measurement of visceral and subcutaneous fat content * fundus photography * body composition analysis 5 outcome evaluation 1）. primary outcomes: cardiovascular mortality, non-fatal myocardial infarction, or non-fatal stroke events. 2）. secondary outcomes: all vascular events, changes in cardiovascular biomarkers, and degree of arterial stiffness.


Eligibility criteria:
inclusion criteria: 1. employed or retired individuals aged 45 years or older; 2. willing to sign an informed consent form and voluntarily participate in health examinations and related data collection. exclusion criteria: 1. history of myocardial infarction, ischemic or hemorrhagic stroke, or revascularization of coronary, carotid, or peripheral arteries; 2. employees with severe psychological disorders who are unable to cooperate with the study; 3. pregnant or breastfeeding women.
advanced hiv prevention (prep chicago)

Conditions: HIV

Summary: this study will evaluate the feasibility of a network intervention to train individuals to disseminate prep information and motivate initial prep interest and knowledge of prep in their social networks.

the specific aims of this study are: 1. to recruit 450 participants in chicago, illinois, and to train them as peer change agents (randomized to cross-over groups) to disseminate prep information and motivate prep interest and knowledge of prep in their local networks. 2. to evaluate feasibility of the program over 2 years of participant follow-up through: 1) peer change agent exit survey; 2) peer change agent booster sessions; 3) peer change agent communication with university of chicago prep program social media; 4) referrals into the project and; 5) calls into the prep warmline.

Eligibility criteria:
inclusion criteria: * lives on the south side of chicago, illinois * born male * has had sex with men in the previous year * is an active facebook user * does not have plans to leave chicago exclusion criteria: -

Keywords: pre-exposure prophylaxis (prep) diffusion of innovation men who have sex with men lgbt african american black hiv network analysis network intervention
cardiovascular effects of covid-19

Conditions: COVID-19

Summary: cardiometabolic disease may confer increased risk of adverse outcomes in covid-19 patients by activation of the aldose reductase pathway, a trigger of the inflammatory cascade. the study team hypothesizes that aldose reductase inhibition with at-001 (caficrestat) might represent a novel therapeutic approach to reduce inflammation and risk of adverse outcomes in diabetic patients with covid-19. an open-label pilot study to assess safety, tolerability and efficacy of at-001 in hospitalized covid-19 patients with history of diabetes mellitus and heart disease will be conducted. eligible participants will be treated with at-001 1500 mg twice daily for up to 14 days. safety, tolerability, survival and length of hospital stay data were compared with matched controls from a contemporaneous registry of covid-19 patients.


Eligibility criteria:
inclusion criteria registry study: in order to be eligible to participate in the registry study, an individual must meet all of the following criteria: 1. age ≥18 years of age 2. hospitalized at one of the participating nyulh locations 3. confirmed covid-19 infection interventional study: in order to be eligible to participate in the registry study, and individual must meet all of the inclusion criteria of the registry study plus the following criteria: 1. hospitalized at nyu tisch 2. history of diabetes mellitus or blood glucose measurement \>126 mg/dl and either 3. history of hypertension and/or ischemic heart disease and/or heart failure or 4. other co-morbid condition that in the opinion of the pi increases risk of heart or lung injury related to the aldose reductase pathway exclusion criteria registry study: an individual who meets any of the following criteria will be excluded from participation in the registry study: 1. persons who have opted out of research participation at nyu 2. pregnancy interventional study: an individual who meets any of the following criteria will be excluded from participation in the interventional study: 1. persons who have opted out of research participation at nyu 2. pregnancy 3. women of childbearing potential 4. breast-feeding women 5. participation in another investigational drug protocol within previous 30 days
finding lcx ami with posterior ecg leads

Conditions: Myocardial Infarction

Summary: along with symptoms of chest pain, the presence of st segment elevations on ecg is the criterion usually used in practice to identify patients with acute coronary artery occlusion and is essential for the direct and acute referral of patients for primary pci. however, ecg does not always reflect changes in the posterior wall of the heart, often equivalent to the left circumflex coronary artery's (lcx) supply area, resulting in an underrepresentation of lcx as culprit artery in stemi populations. there is a general concern that some patients with genuine acute occlusion of lcx may present without st segment elevation and be denied reperfusion therapy, resulting in larger infarction and worse outcome. the aim of this trial is to implement record of posterior ecg leads (v7, v8 and v9) in addition to the standard 12-lead ecg in the pre-hospital setting and to evaluate the clinical impact of this implementation: in comparison to a control cohort of stemi patients diagnosed with a pre-hospital standard 12-lead ecg prior study start, the investigators hypothesize that introducing v7-v9 leads as a clinical routine in the pre-hospital setting will identify patients with stemi involving lcx and with a non-diagnostic standard 12-lead ecg.


Eligibility criteria:
inclusion criteria: intervention group: * all stemi patients referred directly from the pre-hospital setting, treated with primary pci and with available standard 12-lead ecg and ecg with v7-v9 leads. exclusion criteria: * stemi patients treated with primary pci and no ecg with v7-v9 leads.

Keywords: st elevation lcx artery
fat metabolism in response to acute diet- and exercise-induced changes in energy balance

Conditions: Cardiovascular Diseases

Summary: this study is being conducted to learn more about the role of diet and exercise in regulating plasma triglyceride (fat) metabolism. the investigators will examine the effect of acute (24 hour) changes in energy intake and expenditure on fat metabolism the following day.

excess body fat and a sedentary lifestyle are associated with increased plasma triglyceride (tg) and apolipoprotein b-100 (apob-100) concentrations, which are important risk factors for the development of cardiovascular disease. weight loss and endurance exercise improve plasma lipid and lipoprotein concentrations. however, the mechanisms responsible for this effect are largely unknown, and much uncertainty remains regarding the independent roles of dietary energy intake, exercise energy expenditure, and net energy balance in controlling plasma tg concentrations. the main goal of this project, therefore, is to investigate the mechanisms by which acute alterations in energy balance, induced by diet and/or physical activity (endurance exercise), regulate very-low density lipoprotein (vldl) metabolism. subjects will be asked to perform 3 separate trials. one of these will always be an "energy balance" trial that will act as the control trial for the other 2 trials they perform. subjects will therefore be randomized to 2 different study arms.

Eligibility criteria:
inclusion criteria: * overweight and obese men * normal to mild hypertriglyceridemia exclusion criteria: * smoking * any medical condition other than increased body weight (e.g. diabetes, heart disease, etc.). * use of drugs known to affect lipid metabolism (e.g. statins, etc.). * regular exercise training.

Keywords: fat metabolism exercise liver lipoproteins triglycerides
study of the effectiveness and clinical practice use of glecaprevir plus pibrentasvir in patients with chronic hepatitis c genotypes 1 to 6

Conditions: Hepatitis C

Summary: the interferon- and ribavirin- (rbv) free combination regimen of glecaprevir plus pibrentasvir (gle/pib) for the treatment of genotypes 1 to 6 of chronic hepatitis c (chc) viral infection has been shown to be safe and effective in randomized controlled clinical trials. this observational study is an effectiveness research examining the regimen of gle/pib, used according to local label, under real world conditions in a clinical practice patient population.


Eligibility criteria:
inclusion criteria: * participants are treatment-naïve or treatment-experienced with pegylatedinterferon (pegifn), or ifn, and/or ribavirin (rbv) and/or sofosbuvir (prs) with confirmed chronic hepatitis c (chc), genotypes 1, 2, 3, 4, 5, or 6, with or without compensated cirrhosis, receiving combination therapy with the all oral glecaprevir plus pibrentasvir (gle/pib) regimen according to standard of care, international guidelines and in line with the current local label. * participants may be enrolled up to 4 weeks after treatment initiation * participants must not be participating or intending to participate in a concurrent interventional therapeutic trial. exclusion criteria: none.

Keywords: chronic hepatitis c sustained virological response chronic hepatitis c genotype 1 chronic hepatitis c genotype 2 chronic hepatitis c genotype 3 chronic hepatitis c genotype 4 chronic hepatitis c genotype 5 chronic hepatitis c genotype 6
bleeding incidence in vwd patients undergoing on-demand treatment

Conditions: Von Willebrand Diseases

Summary: the purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with vwd undergoing on-demand treatment with a vwf-containing product over a period of 6 months. the data obtained will be used as a basis for historical comparisons with the bleeding and treatment pattern obtained from a clinical study on the efficacy of prophylactic treatment with a vwf/fviii concentrate.


Eligibility criteria:
inclusion criteria: patients who meet all of the following criteria are eligible for the study: * male or female patients aged ≥5.5 years at the time of enrolment * vwd type 1 (baseline von willebrand factor activity \[vwf:rco\], \<30 iu/dl), 2a, 2b, 2m, or 3 according to medical history requiring substitution therapy with a vwf-containing product to control bleeding * currently receiving frequent on-demand treatment with a vwf-containing product * in female patients of child-bearing potential using hormonal contraception, the medication class should remain unchanged for the duration of their study participation * voluntarily given, fully informed written and signed consent obtained before collection of any patient data exclusion criteria: patients who meet any of the following criteria are not eligible for the study: * patients currently on prophylaxis for vwd (except for perioperative prophylaxis) as well as patients having received treatment once a month for menstrual bleeding, but not for any other bleeds * patients whose vwd treatment is planned to be switched from on-demand to prophylactic treatment in the next 6 months * history, or current suspicion, of vwf or fviii inhibitors * medical history of a thromboembolic event within 6 months before enrolment * severe liver or kidney diseases as described in the medical records * female patients with an existing or suspected pregnancy or who are breast-feeding at the time of enrolment * change in hormonal contraception within 6 months before enrolment * cervical or uterine conditions causing abnormal uterine bleeding (including infection or dysplasia) * other coagulation disorders or bleeding disorders due to anatomical reasons * participation in an interventional clinical study during the 6-month of study period * inability to complete the patient diary to reliably evaluate the type, frequency, and treatment of bes during the 6-month study period
hysteroscopic evaluation of cesarean scar defect

Conditions: Cesarean Scar Defect

Summary: the aim of this study is to identify hysteroscopic findings of cesarean scar defect in women underwent at least one prior cesarean section and its relation to any of the different un explained gynecological presentations.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 35 years. 2. had at least one prior cesarean section exclusion criteria: 1. history of uterine surgery that could change the cavity anatomy. 2. uterine abnormalities as submucous fibroid, endometrial or endocervical polyps. 3. recent intra-uterine contraceptive device (iucd) in place. 4. known history of endometriosis
effects of gw876008 on the bowel in patients with irritable bowel syndrome

Conditions: Irritable Colon

Summary: the purpose of this study is to see if gw876008 in irritable bowel syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.


Eligibility criteria:
inclusion criteria: * must have irritable bowel syndrome. exclusion criteria: * subjects who have been taking any medication for the treatment of irritable bowel syndrome within 6 months prior to the start of the study.

Keywords: ibs stress crf1